RUNX2 and breast cancer: Functional analyses demonstrated that the AMPK-RUNX2-mTORC2 signaling axis promotes epithelial-mesenchymal transition (EMT) and enhances the bone metastatic potential of breast cancer cells.<h4>Discussion</h4>These findings reveal a context-dependent role of metformin in modulating metastatic signaling pathways through the AMPK-RUNX2-mTORC2 axis.